BioCentury
ARTICLE | Clinical News

Momenta pauses enrollment in necuparanib trial

November 14, 2015 1:56 AM UTC

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) said it temporarily paused enrollment in the Phase II portion of a Phase I/II trial of necuparanib ( M402) to treat metastatic pancreatic cancer. The company expects to resume enrollment after instituting a protocol amendment that will standardize its methods for diagnosing and managing thrombocytopenia.

An independent data safety monitoring board (DSMB) recommended the measures after it discussed thrombocytopenia, risk of bleeding and thromboembolic events. Necuparanib, a heparin-derived candidate, was designed to have low anticoagulant activity while maintaining antitumor properties previously established for heparinse (see BioCentury, Dec. 15, 2014). ...